AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Allergan first set up on a greenfield site outside Westport 47 years ago and it has provided a bonanza to the Co Mayo town.

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie reported ...

During the 1960s, Abbott entered the Japanese market through a joint venture with Dainippon Pharmaceutical Co., Ltd ... The creation of AbbVie In 2011, Abbott announced it was to separate into ...

Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

Yochi Slonim, co-founder and CEO of Anima, said: “We are excited to partner with AbbVie, a recognised global leader in oncology and immunology, and are looking forward to start working with ...